D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 63 Citations 11,388 176 World Ranking 2102 National Ranking 181

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Cytokine
  • Internal medicine

Arthritis, Immunology, Rheumatoid arthritis, Tumor necrosis factor alpha and Cytokine are his primary areas of study. Richard O. Williams interconnects Inflammation, T cell, Blockade and Pathology in the investigation of issues within Arthritis. His Type II collagen, Synovial membrane, Pathogenesis, Proinflammatory cytokine and Interleukin 17 study are his primary interests in Immunology.

His Type II collagen study combines topics in areas such as C57BL/6 and Autoimmune disease. Within one scientific family, he focuses on topics pertaining to Antibody under Rheumatoid arthritis, and may sometimes address concerns connected to Immunotherapy. His work deals with themes such as Interleukin, Analgesic and Monoclonal antibody, which intersect with Tumor necrosis factor alpha.

His most cited work include:

  • Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. (934 citations)
  • Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen‐induced arthritis (293 citations)
  • Interleukin-10 inhibition of the progression of established collagen-induced arthritis. (243 citations)

What are the main themes of his work throughout his whole career to date?

Richard O. Williams focuses on Immunology, Arthritis, Rheumatoid arthritis, Tumor necrosis factor alpha and Inflammation. His research brings together the fields of Disease and Immunology. His studies in Arthritis integrate themes in fields like Proinflammatory cytokine, Monoclonal antibody, Pharmacology and Pathology.

His work in Rheumatoid arthritis addresses issues such as Psoriasis, which are connected to fields such as Ankylosing spondylitis. His Tumor necrosis factor alpha study integrates concerns from other disciplines, such as Alpha, Monoclonal, Blockade, Necrosis and Interleukin. His Cytokine research integrates issues from Pathogenesis and Synovial membrane.

He most often published in these fields:

  • Immunology (56.04%)
  • Arthritis (44.93%)
  • Rheumatoid arthritis (43.48%)

What were the highlights of his more recent work (between 2015-2021)?

  • Immunology (56.04%)
  • Arthritis (44.93%)
  • Inflammation (19.81%)

In recent papers he was focusing on the following fields of study:

Richard O. Williams mainly investigates Immunology, Arthritis, Inflammation, Rheumatoid arthritis and Immune system. His research combines Genetic association and Immunology. His Arthritis research includes themes of Regulatory T cell, Antibody, Biomarker and Dexamethasone.

His Inflammation research includes elements of Kynurenine pathway, Kynurenine, Cell, Cancer research and Pharmacology. The Rheumatoid arthritis study combines topics in areas such as Autoimmunity, Monoclonal antibody and Downregulation and upregulation. His Immune system research is multidisciplinary, incorporating perspectives in Proinflammatory cytokine, Autoimmune disease and Antigen.

Between 2015 and 2021, his most popular works were:

  • Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial (101 citations)
  • Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial (53 citations)
  • Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of T cell-mediated immune responses. (41 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Immune system
  • Cancer

The scientist’s investigation covers issues in Immunology, T cell, Arthritis, Inflammation and Immune system. Richard O. Williams studies Tumor necrosis factor alpha which is a part of Immunology. His research integrates issues of Receptor and Rheumatoid arthritis in his study of T cell.

His work investigates the relationship between Arthritis and topics such as Biomarker that intersect with problems in Kynurenine pathway, Neurodegeneration, Huntington's disease, Regulatory T cell and Kynurenine. As a part of the same scientific study, Richard O. Williams usually deals with the Inflammation, concentrating on Autoimmune disease and frequently concerns with DNA methylation, Tumor necrosis factor receptor 2, Phenotype, FOXP3 and Proinflammatory cytokine. His Immune system study combines topics in areas such as In vitro, Antibody, Arginine and Protein-Arginine Deiminases.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.

Richard O. Williams;Marc Feldmann;Ravinder N. Maini.
Proceedings of the National Academy of Sciences of the United States of America (1992)

1288 Citations

Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen‐induced arthritis

Claudia Mauri;Richard O. Williams;Marita Walmsley;Marc Feldmann.
European Journal of Immunology (1996)

373 Citations

Interleukin-10 inhibition of the progression of established collagen-induced arthritis.

Marita Walmsley;Peter D. Katsikis;Erika Abney;Sarah Parry.
Arthritis & Rheumatism (1996)

332 Citations

Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease.

Ravinder N. Maini;Michael J. Elliott;Fionula M. Brennan;Richard O. Williams.
Immunological Reviews (1995)

274 Citations

Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis.

Richard O. Williams;Lesley J. Mason;Marc Feldmann;Ravinder N. Maini.
Proceedings of the National Academy of Sciences of the United States of America (1994)

248 Citations

RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: A different interpretation of redundancy

Shlomo Nedvetzki;Erez Gonen;Nathalie Assayag;Reuven Reich.
Proceedings of the National Academy of Sciences of the United States of America (2004)

245 Citations

Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells

Clare A. Notley;Julia J. Inglis;Saba Alzabin;Fiona E. McCann.
Journal of Experimental Medicine (2008)

231 Citations

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

Martin Dennis;Gillian Mead;John Forbes;Catriona Graham.
The Lancet (2019)

205 Citations

IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production

Katrina Blazek;Hayley L. Eames;Miriam Weiss;Adam J. Byrne.
Journal of Experimental Medicine (2015)

192 Citations

Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll‐like receptors

Sandra M. Sacre;Mino Medghalchi;Bernard Gregory;Fionula Brennan.
Arthritis & Rheumatism (2010)

186 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Richard O. Williams

Marc Feldmann

Marc Feldmann

University of Oxford

Publications: 98

Jan Vilcek

Jan Vilcek

New York University

Publications: 50

Iain B. McInnes

Iain B. McInnes

University of Glasgow

Publications: 42

Ravinder N. Maini

Ravinder N. Maini

Imperial College London

Publications: 39

Fionula M. Brennan

Fionula M. Brennan

University of Oxford

Publications: 39

Marie-Christophe Boissier

Marie-Christophe Boissier

Université Paris Cité

Publications: 29

Christian Jorgensen

Christian Jorgensen

University of Bergen

Publications: 29

Paul P. Tak

Paul P. Tak

GlaxoSmithKline (United Kingdom)

Publications: 28

Sergei A. Nedospasov

Sergei A. Nedospasov

Lomonosov Moscow State University

Publications: 27

Rikard Holmdahl

Rikard Holmdahl

Karolinska Institute

Publications: 26

Ewa M. Paleolog

Ewa M. Paleolog

University of Oxford

Publications: 26

Wim B. van den Berg

Wim B. van den Berg

Radboud University Nijmegen

Publications: 24

Mi-La Cho

Mi-La Cho

Catholic University of Korea

Publications: 24

Peter C. Taylor

Peter C. Taylor

University of Oxford

Publications: 24

Gordon Langsley

Gordon Langsley

Université Paris Cité

Publications: 24

Florence Apparailly

Florence Apparailly

University of Montpellier

Publications: 22

Trending Scientists

Markus A. Reuter

Markus A. Reuter

Helmholtz-Zentrum Dresden-Rossendorf

Nobutaka Fujii

Nobutaka Fujii

Kyoto University

Jacob J. Plattner

Jacob J. Plattner

Pfizer (United States)

Jean-Michel Gérard

Jean-Michel Gérard

Grenoble Alpes University

Thomas W. Geary

Thomas W. Geary

Agricultural Research Service

Ana Maria Dalcero

Ana Maria Dalcero

National University of Río Cuarto

Stephanie C. Werner

Stephanie C. Werner

University of Oslo

Kim M. Cobb

Kim M. Cobb

Georgia Institute of Technology

William T. Newsome

William T. Newsome

Stanford University

Maarten van den Buuse

Maarten van den Buuse

La Trobe University

Amy J. Jak

Amy J. Jak

University of California, San Diego

Johannes M. F. G. Aerts

Johannes M. F. G. Aerts

Leiden University

Jan Elen

Jan Elen

KU Leuven

Harold D. Holder

Harold D. Holder

Pacific Institute

Paul Hirst

Paul Hirst

Birkbeck, University of London

Something went wrong. Please try again later.